secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-05-11T20:05:35+00:00
Accession:  0001104659-26-058636
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287
--------------------------------------------------------------------------------

- Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.
- Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.
- MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.
- Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.
- New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/0001104659-26-058636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926058636/ganx-20260511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer